SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...

According to IDC 1, "Organizations continue to find themselves at odds with striking the balance between maintaining their Linux operating system environments and the workloads that they support, all ...

RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and GLP-1 ... Research and development expense was $19.0 million for the quarter ended September 30, 2024, compared to ...

This study presents a valuable finding on the molecular mechanisms that govern GABAergic inhibitory synapse function. The authors propose that Endophilin A1 serves as a novel regulator of GABAergic ...

Delhi has so far recorded 472 cases in November, 2,431 in October, 1,052 in September, 256 in August and 76 in July ...